Cullinan Oncology Inc. (CGEM)
10.01
-1.03 (-9.33%)
At close: Jan 14, 2025, 3:59 PM
10.01
-0.01%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 5.88 |
| Market Cap | 582.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.84 |
| PE Ratio (ttm) | -3.52 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.3 |
| Volume | 687,463 |
| Avg. Volume (20D) | 532,909 |
| Open | 11.19 |
| Previous Close | 11.04 |
| Day's Range | 9.50 - 11.31 |
| 52-Week Range | 9.50 - 30.19 |
| Beta | undefined |
About CGEM
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody f...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 8, 2021
Employees 85
Stock Exchange NASDAQ
Ticker Symbol CGEM
Website https://www.cullinanoncology.com
Analyst Forecast
According to 9 analyst ratings, the average rating for CGEM stock is "Buy." The 12-month stock price forecast is $29.5, which is an increase of 194.68% from the latest price.
Buy 77.78%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
+8.44%
Cullinan Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
8 months ago ·
Source
-10.89%
Cullinan Therapeutics shares are trading lower after the company reported Q1 results and provided a corporate update.
